5005 MCCONNELL AVE, LOS ANGELES, CA
Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
David House Appointed Chief Financial Officer at Armata Pharmaceuticals
Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
Amended material disclosure
Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Shareholders Elect Seven Directors at Armata Pharmaceuticals Meeting
Announces First Quarter 2026 Results and Provides Corporate Update
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload